Related Experiment Video
Updated: Dec 12, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
Published on: February 27, 2016
CSAG2 is a cancer-specific activator of SIRT1
1Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Abstract:
SIRT1 is a NAD+ -dependent deacetylase that controls key metabolic and signaling pathways, including inactivating the p53 tumor suppressor. However, the mechanisms controlling SIRT1 enzymatic activity in the context of cancer are unclear. Here, we show that the previously undescribed CSAG2 protein is a direct activator of SIRT1. CSAG2 is normally restricted to expression in the male germline but is frequently re-activated in cancers. CSAG2 is necessary for cancer cell proliferation and promotes tumorigenesis in vivo. Biochemical studies revealed that CSAG2 directly binds to and stimulates SIRT1 activity toward multiple substrates. Importantly, CSAG2 enhances SIRT1-mediated deacetylation of p53, inhibits p53 transcriptional activity, and improves cell survival in response to genotoxic stress. Mechanistically, CSAG2 binds SIRT1 catalytic domain and promotes activity independent of altering substrate affinity. Together, our results identify a previously undescribed mechanism for SIRT1 activation in cancer cells and highlight unanticipated approaches to therapeutically modulate SIRT1.
Insights
A newly discovered protein, CSAG2, directly activates SIRT1 (a deacetylase that inactivates the p53 tumor suppressor). This CSAG2-SIRT1 interaction promotes cancer cell growth and survival, offering new therapeutic targets.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Biology
Background:
- SIRT1 is a key deacetylase regulating metabolism and signaling, including p53 tumor suppressor inactivation.
- Mechanisms controlling SIRT1 activity in cancer remain largely unknown.
Purpose of the Study:
- To identify novel regulators of SIRT1 activity in cancer.
- To investigate the role of the previously undescribed CSAG2 protein in SIRT1 function and cancer.
Main Methods:
- Biochemical assays to determine CSAG2 interaction with SIRT1.
- Enzymatic activity assays measuring SIRT1 deacetylation of substrates, including p53.
- In vivo tumorigenesis studies and in vitro cancer cell proliferation assays.
Main Results:
- CSAG2 directly binds to and activates SIRT1 enzymatic activity.
- CSAG2 re-expression in cancers enhances SIRT1-mediated p53 deacetylation and inhibition.
- CSAG2 is essential for cancer cell proliferation and promotes tumor growth in vivo.
- CSAG2 activates SIRT1 via direct binding to its catalytic domain, independent of substrate affinity changes.
Conclusions:
- CSAG2 is a novel, direct activator of SIRT1, particularly relevant in cancer.
- CSAG2-mediated SIRT1 activation provides a new mechanism for controlling p53 and promoting cancer cell survival.
- Targeting the CSAG2-SIRT1 interaction presents a potential therapeutic strategy for cancer treatment.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Inhibition of Cdk Activity
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation

